Table 3.
Validation Analysis of Locoregional RFS, With Nomogram Points Segregated Into Tertiles
| Characteristic | Statistic | Hazard Ratio (95% CI) | P | C-Statistic (95% CI) |
|---|---|---|---|---|
| Nomogram Points | /10 points | 0.89 (0.87–0.91) | <.001 | 0.681 (0.666–0.716) |
| Locoregional RFS | n | Median Years (95% CI) | Expected 12-Month RFS, %a | Observed 12-Month RFS (%, 95% CI)a |
| 0–80 Points | 357 | 1.5 (1.1–2.2) | 62.0 | 60.1 (53.7–65.8) |
| 81–142 | 399 | 6.3 (3.5-NR) | 78.0 | 81.1 (76.4–85.0) |
| ≥143 | 326 | 8.1 (7.6-NR) | 90.0 | 92.5 (88.7–95.0) |
| Nomogram Points | /10 points | 0.91 (0.89–0.93) | <.001 | 0.641 (0.627–0.667) |
| Locoregional RFS | n | Median Years (95% CI) | Expected 12-Month RFS, %a | Observed 12-Month RFS, % (95% CI)a |
| 0–80 Points | 509 | 2.1 (1.6–2.4) | 62.0 | 66.6 (61.6, 71.1) |
| 81–142 | 283 | 7.1 (4.6–8.8) | 78.0 | 88.5 (84.0, 91.8) |
| ≥143 | 229 | 10.9 (8.3–14.8) | 90.0 | 92.3 (87.8, 95.2) |
Abbreviations: NR = not reached; RFS = relapse-free survival.
a
Expected 1-year estimates are on the basis of the nomogram estimates; median and observed 12-month RFS are on the basis of actual observed data, using the Kaplan–Meier estimator.